EXOZ — EXOZYMES INC.

—
Nasdaq · Health Care · Biotechnology · CIK 2010788 ·
Last close
$3.31
Market Cap
$30.80M
52W High
$16.90
52W Low
$3.24
ADV30
13,715
Next earnings
—
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -3,046,448 -2,238,528 5,862,684 3,258,901 3,671,241
Jun 2026 0 — -2,953,890 -2,878,614 7,982,355 5,652,696 4,328,255
Mar 2026 0 — -2,386,974 -2,370,247 4,018,841 1,444,562 2,490,741
Dec 2025 0 — -2,695,490 -2,655,036 5,971,517 3,039,343 2,574,268

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-6,995,227
Investing CF
$-145,901
Financing CF
$5,807,966
CapEx
$-196,475
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.16
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-26,353,553
Inventory
—
Receivables
$219,872
ST Investments
—
EBIT TTM
$-10,558,562
Pretax Income TTM
$-10,296,093
Interest Exp TTM
—
Analysts
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -9,716,471 -9,158,734 5,971,517 2,574,268 3,397,249 -6,502,040
Dec 2024 0 -5,932,105 -5,861,335 13,034,404 2,613,629 10,420,775 -8,505,650
Dec 2023 0 -1,796,222 -2,038,389 3,558,509 3,942,828 -384,319 -1,180,870
Dec 2022 0 -1,332,667 -1,396,128 2,685,658 1,313,126 1,372,532 -1,257,096

TTM Snapshot

Revenues TTM
$18,611,051
NetIncome TTM
$-10,190,888
OpCashFlow TTM
—
Assets (Latest)
$7,982,355
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
INMB Inmune Bio, Inc. $29.72M $0.96 —
CVM CEL SCI CORP $32.54M $1.85 —
GNTA Genenta Science S.p.A. $33.03M $0.69 —
KLRS Kalaris Therapeutics, Inc. $34.04M $1.43 —
SAEN Genenta Science S.p.A. $27.82M $0.58 —

News headlines (Yahoo Finance, 1h cache)

eXoZymes to Host Third Quarter 2026 update Conference Call on Thursday, November 19, 2026
2026-11-13 12:20 · Yahoo
eXoZymes CEO to Discuss Commercialization, Key Milestones, and Potential Catalysts in Fireside Chat with Water Tower Research
2026-10-21 20:30 · Yahoo
eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT
2026-09-08 14:20 · Yahoo
EXoZymes Inc (EXOZ) (Q2 2026) Earnings Call Highlights: Strategic Pivot and 10x Productivity ...
2026-08-22 01:03 · Yahoo
MDB Capital Holdings LLC (MDBH) (Q2 2026) Earnings Call Highlights: Strategic Pivots and Asset ...
2026-08-18 01:04 · Yahoo
eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026
2026-08-11 20:10 · Yahoo
eXoZymes Inc. Announces Closing of $6 Million Public Offering
2026-06-17 20:10 · Yahoo
eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast
2026-04-10 13:10 · Yahoo
MDB Capital Holdings Provides Third Quarter 2026 Update
2026-11-17 21:05 · Yahoo
MDB Capital Holdings LLC (MDBH) Q4 2025 Earnings Call Highlights: Strategic Innovations and ...
2026-04-07 01:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.